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ABSTRACT
Exocrine pancreatic insufficiency (EPI) is 
associated with conditions including cystic 
fibrosis (CF), chronic pancreatitis (CP), and 
pancreatic surgery (PS). The symptoms 
include maldigestion, malnutrition, weight 
loss, flatulence, and steatorrhea. Pancreatic 
enzyme replacement therapy (PERT) is the 
standard treatment for EPI; it is regulated in 
many countries and most recently in the USA 
following a US FDA mandate for all PERT 
manufacturers to submit new drug applications. 
Pancrelipase delayed-release capsules (CREON®, 




in Europe since 1984 and in the USA since 1987; 
a new formulation was the first PERT to gain 
approval in the USA in 2009. The efficacy and 
safety of CREON have been demonstrated in 
double-blind, randomized, placebo-controlled 
trials in patients with CF aged ≥7 years and in 
patients with CP or post-PS. The data consistently 
demonstrate significantly better fat and nitrogen 
absorption with CREON versus placebo, and 
improvements in clinical symptoms, stool 
frequency, and body weight. Additionally, 
efficacy and safety of CREON have been shown 
in open-label studies in young children with CF 
(aged 1 month to 6 years), with control of fat 
malabsorption and control of clinical symptoms. 
The most commonly reported adverse events 
(AEs) with PERT are gastrointestinal disorders 
and allergic skin reactions. In clinical studies, 
CREON was well tolerated with very few 
withdrawals due to AEs and a low frequency 
of AEs judged treatment related, regardless of 
patient age. To further support the known safety 
profile of PERT, all manufacturers are required to 
investigate risk factors for fibrosing colonopathy, 
a rare gastrointestinal complication of CF, and 
the theoretical risk of viral transmission from 
porcine-derived PERT products. Together, 
the clinical study data and wealth of clinical 
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experience suggest that CREON is effective and 
safe in patients with EPI regardless of etiology, 
with a very favorable risk-benefit profile.
Keywords: chronic pancreatitis; CREON®; cystic 
fibrosis; delayed-release; exocrine pancreatic 
insufficiency; pancreatin; pancreatic enzyme 
replacement therapy; pancrelipase
INTRODUCTION
Pancreatic enzyme replacement therapy 
(PERT) products are prescribed for the treatment 
of exocrine pancreatic insufficiency (EPI), which 
is often associated with cystic fibrosis (CF), 
chronic pancreatitis (CP), malignant ductal 
obstruction of the pancreas, or pancreatic 
surgical procedures.1 The pancreas secretes 
digestive enzymes (lipase, protease, and amylase) 
into the duodenal lumen, where they facilitate 
the breakdown of macronutrients. Thus, patients 
with untreated EPI typically have difficulty 
digesting fat and suffer symptoms of both 
maldigestion and malnutrition, with deficiencies 
of essential fatty acids and fat-soluble vitamins, 
weight loss, cramping, flatulence, bloating, and 
greasy, foul-smelling, loose stools (steatorrhea). 
The overt clinical symptoms of EPI are mainly 
a consequence of fat maldigestion. However, 
protein and carbohydrate maldigestion also 
contribute to EPI-associated malnutrition, 
affecting nutritional status and overall health. 
Protein maldigestion results in excess protein 
in the stool (creatorrhea) and chronic protein 
malabsorption may result in hypoalbuminemia, 
which can lead to generalized edema or ascites. 
Symptoms of carbohydrate malabsorption 
include diarrhea, flatulence, and abdominal 
pain/distension. For patients with CF, inadequate 
treatment of EPI may have serious consequences 
for nutritional status, which has been directly 
correlated with lung function2,3 and survival.4,5
By convention, PERT products are labeled 
according to the amount of lipase they contain; 
all PERT products also contain protease and 
amylase, but the labeled and actual amounts of 
these two enzymes may differ from product to 
product even when labeled lipase amounts are 
the same. Older pancreatic enzyme formulations 
were based on pancreatin, a substance obtained 
from the pancreas of the hog or ox. Current PERT 
formulations are based on pancrelipase, a more 
potent extract from the hog pancreas, which the 
US Pharmacopeia (USP)6 defines as containing 
not less than 24 USP units of lipase activity, 
100 USP units of amylase activity, and 100 USP 
units of protease activity per mg. International 
application of these definitions is somewhat 
confusing, because outside the USA pancrelipase 
is typically referred to as “pancreatin” even 
though it is the same active substance with 
similar potency and activity.
For exogenous PERT to be effective, it is 
crucial that as much as possible of the dose 
reaches the proximal small intestine at the same 
time as the partially digested food (chyme). 
Lipase is the most sensitive of the pancreatic 
enzymes to the effects of both pepsin and acid, 
and is irreversibly inactivated at pH 4.0 or lower.7 
Early PERT preparations consisting of tablets or 
encapsulated powder were not protected against 
such inactivation in the stomach, and perhaps 
only as little as 8% of ingested lipase was 
bioavailable in the small intestine. Therefore, 
it was necessary to administer orally up to five 
to 10 times as much lipase as was required 
for intraluminal digestion; bicarbonate or H2 
receptor antagonists were often administered 
concomitantly to attempt to reduce degradation 
by stomach acid. The development of enteric 
coatings and microsphere and microtablet 
formulations in the 1970s made it possible to 
protect pancreatic enzymes for passage through 
the stomach, enabling enzyme delivery to the 
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duodenum simultaneously with the chyme, 
and thus allowing enzyme release when the 
intestinal pH is most conducive for enzyme 
activity. This allowed patients with CF to shift 
from the previously recommended low-fat, 
high-protein program to a diet high in fat as 
well as protein, making it possible for them 
to meet their high energy needs. Subsequent 
refinements in microencapsulation technology 
have facilitated increases in lipase content and 
more efficient dosing.8,9
Previous studies have suggested that PERT 
products vary in terms of actual enzyme content 
and in-vitro response to simulated gastric and 
duodenal conditions.10-12 As pancreatic enzymes 
are sensitive proteins and liable to inactivation, 
capsules were routinely overfilled to ensure 
that potency would not drop below label 
claims before the end of shelf-life.13 Over the 
past decade, the USP standard has evolved in 
recognition of these circumstances and actually 
states upper and lower limits of labeled amounts 
of enzymes. Currently, the US Food and Drug 
Administration (FDA) labeling requirements 
mandate that approved pancreatic enzymes in 
the USA have no stability overfill and hence new 
preparations are labeled accordingly.
PERT products are approved around the world; 
however, because PERT products were available 
before the passage of the 1938 Federal Food, Drug, 
and Cosmetic Act, they have historically been, in 
the absence of any specific concerns, marketed in 
the USA without any requirements for safety and 
efficacy testing. These prescribed products have 
been documented with in-vitro performance 
studies and in-vivo clinical efficacy data.12-18 
Citing concerns about the significant differences 
in bioavailability among PERT products and 
consequent instances of serious under- and 
over-dosing, the FDA formally announced in 
2004 the New Drug Application requirement for 
EPI drug products,19 with the stipulation that 
because the drugs are “medically necessary,” 
manufacturers could continue to market their 
products without an approved application for the 
next 4 years, which was extended until May 2010. 
To date, three pancreatic enzyme preparations are 
on the market in the USA that have received FDA 
approval: CREON® (pancrelipase delayed-release 
capsules; Abbott, Marietta, GA, USA) in April 
2009, Zenpep® ([pancrelipase] Delayed Release 
Capsules; Eurand Pharmaceuticals Ltd, Yardley, 
PA, USA) in August 2009, and Pancreaze 
([pancrelipase] delayed-release capsules; McNeil 
Pharmaceuticals, Ruritan, NJ, USA) in April 
2010. These products represent the first enteric-
coated pancrelipase preparations approved in 
the USA since the introduction of crude extracts 
over 50 years ago to treat infants with CF, and 
all are of porcine origin. As new dosage forms are 
approved, some manufacturers have taken the 
opportunity to modify their formulations with 
regards to excipients, improved packaging, and 
stability to allow for a more consistent delivery 
of pancreatic enzymes.
CREON INDICATIONS AND 
PRESCRIBING INFORMATION
CREON is indicated for the treatment of 
EPI due to CF, CP, pancreatectomy, and other 
conditions in which EPI is present.20 Dosages are 
individually titrated based on clinical symptoms 
and the degree of steatorrhea, and are adjusted 
for the amount of dietary fat consumed. For 
patients with CF, guidelines from the CF 
Consensus Conferences21-24 are used for initiating 
PERT and are summarized in Table 1. Dosing in 
patients with CF and CP will also be discussed 
in later sections. CREON capsules should be 
swallowed whole and not crushed or chewed. 
Capsules can be opened and the contents given 
on a spoon mixed with soft acidic food, such 
as applesauce, until children are able to swallow 
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capsules whole; this mixture should be given 
during meals, immediately after mixing.20 If 
capsules are opened, care should be taken to mix 
the contents only with foods of pH ≤4.5 to avoid 
disruption of the protective enteric coating and 
thus early release of enzymes and/or loss of 
enzyme activity before ingestion.20 As CREON 
is an enteric-coated formulation and therefore 
protected against gastric acid inactivation, 
routine administration of a concomitant proton 
pump inhibitor or H2 receptor antagonist is not 
required.
The active pharmaceutical ingredient of 
CREON is pancrelipase, a porcine pancreatic 
extract containing multiple enzyme classes. 
Each delayed-release gelatin capsule for oral 
administration contains enteric-coated spheres 
approximately 1 mm in diameter.20 The 
following inactive ingredients are also present 
in the current FDA-approved formulation: cetyl 
alcohol, dimethicone, hypromellose phthalate, 
polyethylene glycol, and triethyl citrate.20 
The inactive ingredients differ from previous 
formulations in that light mineral oil has been 
removed from the spheres and dibutyl phthalate 
has been removed from the enteric coating in 
response to general FDA and European Union 
directives, respectively.
By convention, PERT preparations listed 
with a numerical value refer to the thousands of 
units of lipase per dosage form contained in the 
product. In the USA, USP standards are used for 
pancrelipase, while in Europe other standards 
are used including European Pharmacopoeia (Ph. 
Eur.)/Fédération Internationale Pharmaceutique 
(FIP) units. Standardization of lipase units has 
occurred (1 USP=1 Ph. Eur.=1 FIP unit) but there 
are differences with regards to amylase and 
protease unit standards. As PERT is traditionally 
dosed based on lipase units, we can use 
them interchangeably and no conversion is 
needed.26,27
Enteric-coated (delayed-release) CREON 
formulations have been available in Europe since 
1984 and in the USA since 1987. Currently, in 
the USA, CREON is available in three strengths, 
containing 6000, 12,000, and 24,000 USP units 
of lipase per capsule.20 In addition, protease and 
amylase are included in these preparations in 
the amounts shown in Table 2.
Other formulations of CREON (with the same 
active ingredient) are available outside the US 
(Creon 10000 Ph. Eur., Creon 25000 Ph. Eur., 
Creon 40000 Ph. Eur. and a special formulation 
Table 1. Cystic Fibrosis Consensus Conference dosing guidelines for pancreatic enzyme replacement therapy.21-25
Infants up to 12 months 2000-4000 IU lipase/120 mL of formula or per breast feeding
Children 12 months to 4 years 1000 IU lipase/kg body weight/meal to a maximum of 
  2500 IU/kg body weight/meal (daily maximum of 
  10,000 IU/kg/day or 4000 IU/g dietary fat/day)
Children 4 years and older and adults 500 IU lipase/kg body weight/meal to a maximum of 
  2500 IU/kg body weight/meal (daily maximum of 
  10,000 IU/kg/day or 4000 IU/g dietary fat/day)
IU=international unit.
Table 2. CREON dosage forms and strengths currently 
available in the USA.20
 USP units
 Lipase Protease Amylase
CREON 6,000 6000 19,000 30,000
CREON 12,000 12,000 38,000 60,000
CREON 24,000 24,000 76,000 120,000
USP=United States Pharmacopeia.
The 6000, 12,000, and 24,000 strengths are equivalent in 
lipase activity to previously available Creon 5, 10, and 20, 
respectively. 
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for children, Creon micro [5000 Ph. Eur. lipase 
units per dosing scoop]).
CYSTIC FIBROSIS
Overview of Exocrine Pancreatic 
Insufficiency in Cystic Fibrosis and 
Long-term Consequences
EPI is present in approximately 85% of 
patients with CF overall and in up to 99% of 
patients who are F508del homozygotes, most 
often from birth.28-30 The clinical triad of 
increased appetite, steatorrhea, and malnutrition 
is highly suggestive of CF with EPI. Nowadays, 
with increasing worldwide implementation of 
newborn screening programs,31 CF is usually 
diagnosed in very early life. Nevertheless, at 
initial consultation, half of all infants with CF 
are symptomatic for EPI and the majority present 
with impaired growth, low body weight, and 
digestive symptoms.32 In addition to malnutrition 
and steatorrhea, other frequent symptoms 
include abdominal pain, bloating, flatulence, and 
rectal prolapse.27,33 EPI can also lead to edema 
caused by hypoalbuminemia, deficiencies in fat-
soluble vitamins, and hemolytic anemia related 
to vitamin E deficiency. Even in the context of 
symptoms, a laboratory test to define pancreatic 
function status or confirm fat excretion levels 
is recommended.21,27 The fecal elastase-1 test is 
highly sensitive (using a monoclonal rather than 
polyclonal antibody) and involves an enzyme-
linked immunosorbent assay to determine 
levels of this human pancreas-specific enzyme 
in a small specimen of well-formed feces; thus 
it is simply a diagnostic tool of pancreatic 
function.34,35 Assessment of the coefficient of 
fat absorption (CFA) involves 72-hour stool 
collection, recording of dietary fat during the 
stool collection period, and calculation of the 
percentage CFA.36,37 This test, which is very 
cumbersome for the patient, is the most valuable 
tool for assessing fat maldigestion in PERT-
supplemented patients with poor nutritional 
status or inadequately controlled gastrointestinal 
symptoms, or in clinical trials to evaluate PERT 
efficacy.
It has been documented that newborn 
screening programs for CF confer nutritional 
advantages, as a result of earlier diagnosis, 
compared with traditional CF diagnosis based on 
clinical symptoms.38 As better nutritional status 
and growth is strongly associated with improved 
pulmonary function and improved survival in 
CF,2-4,39 prompt nutritional support and PERT 
should be provided as soon as EPI is confirmed, 
whatever the patient’s age and mode of feeding, 
in order to maintain normal growth status.
Current Recommendations and Practice 
for the Treatment of Exocrine Pancreatic 
Insufficiency in Cystic Fibrosis
The standard of care for EPI is based on 
oral PERT, regardless of etiology. The dosing 
guidelines for patients with CF are summarized 
in Table 1.21-25 The occurrence in the 1990s of 
fibrosing colonopathy (FC) in young children 
receiving very high daily doses of PERT40,41 had a 
major impact on PERT prescriptions, despite the 
rarity of this severe gastrointestinal complication. 
As a result, consensus guidelines for PERT 
published in 1995 and 2002 recommended that 
daily doses should not exceed the equivalent 
of 10,000 IU lipase/kg/day or 4000 IU lipase/g 
dietary fat/day.21-23 However, it should be noted 
that these dosing recommendations were 
based on older PERT formulations, which were 
overfilled in terms of lipase units.11-13,18 Therefore, 
some patients may have been receiving actual 
doses that exceeded the recommended upper 
limit. In the current era of better controlled 
manufacturing processes, and the US FDA 
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requirements for PERT labeling to state actual 
lipase content, these dosing recommendations 
and limits may need to be revisited.
Studies have shown that standard- and 
high-strength PERT preparations provide 
similar efficacy in terms of fat absorption, as 
summarized by Littlewood et al.;27 standard-
strength enzyme preparations are recommended 
for infants and children. Many factors may 
affect enzyme efficacy; dose requirements 
therefore remain approximate and doses should 
be individualized. Adequate PERT should 
enable the patient to eat a normal or high-
fat diet without unpleasant gastrointestinal 
symptoms and to achieve a satisfactory 
nutritional and growth status.27 PERT should 
be given with all fat- and protein-containing 
foods, according to the dosing guidelines, with 
pancreatic enzyme dosage gradually increased 
on a dietician’s or physician’s advice if needed 
until symptom relief and adequate weight 
gain are achieved. Individualization of doses 
is supported by a recent report of evidence-
based practice recommendations from the 
Cystic Fibrosis Foundation (CFF) Growth and 
Nutrition Subcommittee,25 which concluded 
that there was insufficient evidence for making 
recommendations regarding specific PERT doses 
and CFA values or growth status; there was also 
insufficient evidence to support the efficacy of 
generic PERT formulations.
Efficacy of CREON in Cystic Fibrosis
The efficacy of the various formulations 
of CREON (with the same active ingredient) 
has been confirmed through extensive clinical 
experience and in a number of clinical studies 
in patients with CF.17,42-47 A summary of 
published efficacy data from six clinical studies 
investigating formulations that are currently 
available in either the USA or Europe is provided 
in Table 3. A seventh study reporting use of a 
pre-FDA mandate US formulation (Creon 2017) 
has also been included as this formulation has 
equivalent lipase content per capsule to current 
CREON 24,000 USP, with similar pharmaceutical 
characteristics and sphere size, and therefore 
provides valid efficacy and safety information. 
Four studies had an open-label design without 
placebo control as they included infants and 
young children.44-47 The target lipase doses in 
these studies were selected according to the CFF 
and EU consensus guidelines21-24 relevant to the 
age group under investigation. The three recent 
studies carried out in the USA used the new 
formulation of CREON that is now currently 
available.42-44
The data summarized in Table 3 provide 
substantial evidence for the efficacy of the 
different CREON formulations in significantly 
improving fat absorption (as measured by 
the CFA) versus placebo or baseline (no 
treatment). On-treatment efficacy appears 
to be consistent regardless of study design, 
patient age, and CREON formulation, with 
CREON demonstrating efficacy in improving 
malabsorption in preschool-age children44-46 as 
well as older children and adults. Improvements 
were also seen with CREON in secondary 
outcome measures such as the coefficient of 
nitrogen absorption (CNA), clinical symptoms, 
stool frequency, and body weight (Table 3). The 
CNA is measured in the same way as the CFA 
but with assessment of nitrogen as a marker for 
protein absorption. Comparison of data from two 
randomized, double-blind, placebo-controlled 
studies with the FDA-approved formulation 
of CREON indicates consistent on-treatment 
efficacy in patients aged 7-11 years and patients 
aged ≥12 years: mean CFA 82.8% and 88.6% and 
mean CNA 80.3% and 85.1%, respectively.42,43 
Significant improvements in these parameters 
versus placebo were seen with CREON in both 
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trials and improvements in clinical symptoms 
were also consistent (Table 3). The outcomes 
in the CREON clinical trials compare favorably 
with normal CFA and CNA values; a study of 16 
healthy individuals indicated a mean CFA value 
of 94% and a mean CNA value of 88%.48
Combining individual patient data for 
on-treatment CFA values and changes in CFA 
versus placebo from the two randomized, 
double-blind, placebo-controlled studies with 
the FDA-approved formulation of CREON42,43 
indicated no apparent differences in CFA values 
on-treatment according to the severity of EPI (as 
measured by the CFA during placebo treatment). 
Thus, patients with more severe EPI (lower CFA 
on placebo) had correspondingly larger increases 
in their CFA on CREON treatment, and all 
subjects with a placebo CFA of less than 40% 
had an on-treatment difference from placebo 
of over 30% (Figure 1). No obvious differences 
were observed regarding efficacy of CREON 
for the different age groups (Figure 1). In the 
Trapnell et al.42 study, prospectively planned 
subanalyses showed no differences in terms of 
CFA, CNA, abdominal pain, stool consistency, 
and flatulence between subjects aged 12-18 years 
and those aged >18 years.
Safety of CREON in Cystic Fibrosis
The long-term safety profile of PERT, such 
as CREON, has been described in the medical 
literature, with the most commonly reported 
adverse events being gastrointestinal disorders 
and allergic skin reactions (rash, urticaria).20 
Table 4 summarizes treatment-emergent adverse 
events (TEAEs) occurring in six published clinical 
studies of CREON that report safety data on 
currently available formulations.17,42-46
TEAEs were generally more frequent with 
placebo compared with CREON, reflecting the 
effects of untreated EPI in these patients. The 
majority of patients completed treatment in these 
studies, and there were very few withdrawals 
due to TEAEs, indicating that CREON was well 
tolerated. As expected due to the nature of the 
underlying disease, gastrointestinal disorders 
were the most frequent class of TEAEs on both 
CREON and placebo. There was a low frequency 
of TEAEs judged to be probably or possibly 
treatment related in patients receiving CREON. 
Serious TEAEs were a severe Pseudomonas species 
lung infection and bronchial obstruction in 
the study by Munck et al.46 and hospitalization 
for pulmonary exacerbation in the study by 
Stern et al.17
There were no obvious trends for TEAEs 
in patients with CF by age group. Safety data 
from studies with the new FDA-approved 
formulation42-44 are consistent with those of other 
formulations, with low frequencies of treatment-
related TEAEs and withdrawals due to TEAEs. 
Global post-marketing surveillance data on the 
various CREON formulations have been collected 
since January 1984; no data have been noted 
during this time that would suggest any safety 
issues associated with CREON formulations.49
Taken together, these data indicate that 
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Figure 1. On-treatment coefficient of fat absorption 
(CFA) in the two double-blind, placebo-controlled studies 
with the US Food and Drug Administration-approved 
formulation of CREON in patients with cystic fibrosis: 
difference between on-treatment and placebo CFA as a 
function of placebo CFA (lower placebo CFA indicates 
more severe exocrine pancreatic insufficiency).
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EPI due to CF irrespective of age, highlighting its 
favorable risk–benefit profile in these patients.
CHRONIC PANCREATITIS AND 
OTHER PATIENT POPULATIONS
Overview of Exocrine Pancreatic 
Insufficiency in Chronic Pancreatitis and 
Long-term Consequences
CP is the most common cause of EPI in adults 
and the most common underlying etiology is 
alcohol abuse. In 1788, Cawley reported on a “free 
living young man” who had died of emaciation 
and diabetes whose post mortem examination 
revealed multiple pancreatic calculi.50 Since that 
early description thousands of reports have been 
published. We now know that this multifactorial 
condition is characterized by chronic 
inflammation with subsequent loss of exocrine 
and occasionally endocrine parenchyma, with 
fibrotic tissue replacement, ultimately resulting 
in maldigestion, malnutrition, and diabetes 
mellitus. The exact mechanisms triggering 
and perpetuating the disease are not fully 
understood, but there is a complex interaction 
between noxious stimuli, the environment, and 
genetic predisposition that leads to an excessive 
inflammatory response with subsequent tissue 
destruction. However, our understanding of this 
condition has increased over the past few years 
and molecular and cellular events contributing 
to chronic inflammation with subsequent 
tissue destruction are better understood, 
particularly the important role that genes and 
the environment (alcohol consumption and 
cigarette smoking being independent risk 
factors) play in this complex condition.51,52 Other 
etiologies that lead to EPI include tumors that 
obstruct pancreatic enzyme secretion (pancreatic 
cancer, intraductal papillary mucinous neoplasia, 
ampullary tumors), genetic mutations (CF, 
cationic trypsinogen, chymotrypsin C, and 
serine protease inhibitor Kazal type 1), extensive 
necrotizing pancreatitis, and different types of 
pancreatic surgery (PS), such as local resection, 
longitudinal pancreaticojejunostomy, and total 
pancreatectomy, with EPI severity depending on 
the type and extent of surgery.53,54
Patients with CP usually present with 
chronic recurrent abdominal pain and then, 
over a period of many years, CP may lead 
to steatorrhea (defined as >7 g of fecal 
fat/day while consuming a 100 g fat diet, with 
clinical/symptomatic steatorrhea seen when 
>15 g/day55), malnutrition, and occasionally 
endocrine pancreatic dysfunction, but this may 
vary based on the etiology of CP. Steatorrhea 
occurs in CP only after the pancreatic enzyme 
output has diminished by 90% of normal 
levels.56,57 The large reserve capacity of the 
pancreas noted in earlier studies may be due to 
the non-pancreatic gastric and lingual lipases.58
The diagnosis of CP can be made on the 
basis of clinical symptoms in combination 
with structural and functional criteria, but 
in some patients it can be very difficult to 
make. Structural changes may take years to 
develop and functional tests can be normal or 
not easily accessible; chronic abdominal pain 
may or may not be present. It is important to 
recognize and treat EPI in patients with CP 
to prevent maldigestion of fat, proteins, and 
carbohydrates, malnutrition, and weight loss. 
In healthy individuals, fat-soluble vitamins are 
absorbed from the small intestine along with 
digested dietary fats via micelles (aggregates 
of monoglycerides, fatty acids, and bile salts). 
Deficiencies in fat-soluble vitamins A, E, and K are 
therefore often present in patients with EPI as a 
result of fat maldigestion (and therefore reduced 
micelle formation), and may lead to symptoms 
such as impaired night-time vision, cerebellar 
ataxia, and/or increased prothrombin time,59-61 
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and vitamin B12 deficiency may be present due 
to both impaired release of the B12 complex 
and bacterial overgrowth in the intestine.62 
Compared with healthy controls, patients with 
CP have lower serum levels of vitamin D and 
decreased bone mineral density.63-65
Summary of Current Practice for 
Pancreatic Enzyme Replacement Therapy 
for the Treatment of Exocrine Pancreatic 
Insufficiency in Chronic Pancreatitis
As previously mentioned, the standard 
of care for EPI regardless of underlying 
etiology is oral PERT. There are currently 
few formal dosing guidelines for PERT in CP. 
Approximately 90,000 USP or Ph. Eur. units of 
lipase must reach the duodenum at the same 
time as ingested food to assure maximal fat 
digestion and absorption in patients with 
EPI. As some endogenous lipase secretion 
is usually preserved in CP, a starting dose of 
PERT of 25,000-40,000 USP/Ph. Eur. units of 
lipase per meal is recommended for the vast 
majority of patients,26,66,67 which can then be 
adjusted based on individual clinical need 
(symptom severity, degree of steatorrhea, 
and fat content of diet). To date, there are no 
studies showing that PERT corrects fat-soluble 
vitamin deficiencies or B12 deficiency without 
simultaneous vitamin supplementation.59,62
Efficacy and Safety of CREON in Chronic 
Pancreatitis and Other Populations
Randomized and/or placebo-controlled trials 
of CREON in patients with EPI due to CP or PS 
have shown improvement of steatorrhea, as 
measured by increased fat absorption, reduced 
fecal fat excretion, decreased stool weight 
and frequency, improved stool consistency, 
and improved symptom scores.54,67-71 Another 
prospective study has shown improvement in 
quality of life.72
In a recent randomized, double-blind, 
placebo-controlled study by Whitcomb et al.,71 
a new formulation of CREON 12,000 lipase unit 
(USP) capsules was shown to be safe and effective 
when patients with CP or post-PS were treated 
with 72,000 lipase units (USP) per main meal and 
36,000 lipase units (USP) per snack compared 
with placebo for 7 days following a 5-day 
placebo run-in period (n=54). The change from 
baseline in CFA was significantly greater with 
CREON compared with placebo: mean±standard 
deviation 32.1%±18.5% versus 8.8%±12.5% 
(P<0.0001). Greater improvements from baseline 
in stool frequency, stool consistency, abdominal 
pain, and flatulence were also observed with 
CREON over placebo. TEAEs were reported in 
five patients (20.0%) in the CREON group and 
in six (20.7%) in the placebo group, the most 
common being gastrointestinal events and 
metabolism/nutrition disorders. There were no 
treatment discontinuations due to TEAEs in this 
study.
A prospective, crossover, randomized, 
controlled trial by Domínguez-Muñoz et al.67 in 
24 patients with CP and EPI evaluated the effect 
of the administration schedules of CREON (the 
Creon 10000 formulation currently available in 
Europe). The dosing schedules were four capsules 
before meals (schedule A), four capsules after 
meals (schedule B), or four capsules throughout 
the meal (one before, two during, and one after; 
schedule C). Regardless of the administration 
schedule used, CREON improved fat digestion 
in all patients, with recovery rates of 54% with 
schedule A, 61% with schedule B, and 61% 
with schedule C (all P<0.0001 versus baseline 
value of 24%) using the 13C-mixed triglyceride 
breath test. There was no difference in patients’ 
preference for the three dosing schedules in 
this study. Fat digestion was optimal when 
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the enzyme preparations were taken during or 
after meals, and tended to be better than that 
observed when capsules were administered just 
before meals although the differences were not 
significant; therefore, these results should not be 
used as a recommendation for CREON dosing. 
The US prescribing information for CREON 
recommends administration during meals in 
all patients with EPI;20 however, in practice, 
PERT is often administered before meals as well 
as during meals in patients with CF, whereas 
in non-CF patients it is often administered 
after meals.
In a randomized, double-blind, multicenter, 
placebo-controlled trial, 27 patients with CP 
received four capsules of CREON (Creon 10; a 
pre-FDA mandate formulation with equivalent 
lipase content per capsule to current CREON 
12,000 USP) with each meal (two capsules with 
snacks) for 2 weeks, following a 2-week placebo 
run-in period.70 Patients receiving CREON 
for 2 weeks had a significantly higher mean 
change in CFA compared with those receiving 
placebo: +36.7% versus +12.1% (P=0.0185). 
Compared with placebo, CREON also decreased 
stool frequency (5.2 per day vs. 14.6 per day; 
P=0.0015), controlled steatorrhea (change in 
stool fat excretion –56.6 g/day vs. –11.4 g/day; 
P=0.0181), and improved stool consistency 
(stools became more firm in seven subjects vs. 
one subject; P=0.0102 for overall consistency). 
No major adverse effects were reported in this 
small study.
The efficacy of CREON in maintaining 
postoperative digestion and nutrition in 11 
patients who underwent local resection-
longitudinal pancreaticojejunostomy for CP was 
evaluated in a placebo-controlled trial (using 
Creon 8000, a previous formulation no longer 
available) at different doses based on initial 
daily fat excretion.54 Patients who received 
CREON showed significant improvements in 
the CFA (83.3% vs. 52.7%; P=0.02) and the 
coefficient of total energy absorption (88.3% 
vs. 71.9%; P=0.02) when compared with 
placebo. Of interest, the nutritional status of 
these patients was not significantly altered over 
the period of the study, although four of five 
patients receiving CREON gained more than 3.6 
kg body weight whereas none of the six patients 
receiving placebo gained weight. These data 
suggest that postoperative PERT is necessary and 
effective in improving absorption in patients 





In clinical practice, some patients do not 
respond adequately to PERT and they should 
be encouraged to discuss openly with their 
healthcare team any problems they have. In these 
cases, various other factors may be involved, such 
as lack of patient compliance, suboptimal PERT 
dosing, miscalculation of fat intake, deficiency 
of pancreatic bicarbonate secretion, abnormal 
composition of bile salts, intestinal ion transport 
abnormalities, intestinal inflammation, altered 
gut motility, bacterial overgrowth, and impaired 
absorption of long chain fatty acids.26,66,73 High-
fiber diets have been associated with a small 
but significant increase in fecal fat excretion 
in patients with CP with EPI.74 In addition, 
calcium- and magnesium-containing antacids 
are associated with the formation of soaps and 
the precipitation of glycine-conjugated bile salts 
in the intestine, which may lead to worsening 
of steatorrhea in patients with underlying EPI.75 
Factors related to the PERT preparation itself 
may have an impact, including the size of the 
enzyme particles, the dissolution characteristics 
of the preparation, the rate of emptying from 
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the stomach, and the timing of intake in relation 
to meals. Variations in the enzyme content of 
PERT preparations was a potential consideration 
in the USA before the introduction of the newly 
approved PERT preparations, as noted earlier in 
this review. With the new preparations, this is 
not expected to be an issue.
In compliant patients who do not respond 
to PERT, increasing the dose twofold and 
decreasing the amount of fat in meals may be 
an option in non-CF patients with EPI. Patients 
with EPI commonly have lower pancreatic 
bicarbonate secretion, which may become 
insufficient, resulting in a pH level in the 
duodenum and small intestine that is too low 
for adequate dissolution of the PERT enteric 
coating.21,66,73 While bicarbonate transport is 
difficult to treat, intestinal pH can be raised 
to optimize PERT dissolution by increasing 
the pH of gastric secretions flowing into the 
duodenum. Furthermore, increasing duodenal 
pH may reduce the precipitation of bile salts. 
Thus, if symptoms of maldigestion persist, 
adding an H2 receptor antagonist or a proton 
pump inhibitor may be beneficial in improving 
PERT efficacy,76-78 as is currently prescribed in 
patients with CF. If all of the above fail, other 
digestive conditions that may interfere with 
intestinal absorption should be considered, such 
as bacterial overgrowth, giardiasis, celiac disease, 
or blind loop syndrome after gut surgery.26,66 A 
complete medical assessment is needed in the 
absence of clinical improvement.
POTENTIAL RISKS OF PANCREATIC 
ENZYME REPLACEMENT THERAPY
Fibrosing Colonopathy
FC is a painful condition characterized by 
shortening and fibrosis of the colon,79 and is 
a recognized gastrointestinal complication 
seen almost exclusively in patients with CF. 
Littlewood80 characterized this condition as:
“Severe submucosal thickening by mature •	
fibrous connective tissue
Intraluminal fusiform narrowing but with •	
little change in the external bowel diameter, 
mainly in distal caecum and ascending 
colon
Loss of haustral pattern sometimes with a •	
‘cobblestone’ appearance of the intestinal 
epithelium, although the epithelium is 
generally intact but with some localized 
defects. Altered architecture suggests there 
has been repair of previous damage
Little or no evidence of inflammation or •	
other lesions suggesting Crohn’s disease. 
Some slight inflammation and fat around 
blood vessels
The small bowel is not involved•	
A few patients have chylous ascites.”•	
FC symptoms include abdominal pain, 
diarrhea, hematochezia (bloody stools), and, 
in some cases, partial or complete abdominal 
obstruction where significant narrowing or 
stricture has occurred. Treatment of FC ranges 
from reduction in excessive doses of pancreatic 
enzymes to surgery (eg, partial or total colonic 
resection).
The first reported case of FC in the USA 
occurred in 199181 and five cases occurring in 
Europe had been reported by 1993.82 The only 
apparent common factor in these cases was a 
switch from standard- to high-strength PERT. 
Before PERT dosing guidelines were established 
in 1995, more than 60 cases were reported 
worldwide.83 Despite the voluntary withdrawal 
of high-strength formulations by manufacturers 
in early 1994, and the 1995 CF Consensus 
Conference recommendations that daily dosages 
should not exceed 10,000 IU lipase per kg body 
weight,22 37 cases of FC had been identified 
in the USA alone between 1995 and 1999.84 
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Early reports of FC in the USA led the CFF in 
collaboration with the FDA to perform a case-
controlled study to investigate FC.40 This and 
another case-control study showed a very strong 
association with the use of high doses of both 
standard- and high-strength PERT, usually over a 
prolonged period of time.40,41 Other possible risk 
factors identified for FC in one case-controlled 
study included previous intestinal surgery, 
meconium ileus, distal intestinal obstruction 
syndrome, and use of H2 receptor antagonists, 
corticosteroids, and recombinant human 
DNase.40
The underlying pathogenesis of FC remains 
unclear and mechanisms other than previous 
exposure to high doses of PERT are under 
discussion. According to the current literature, an 
association between FC and intake of methacrylic 
acid copolymer (Eudragit®, Evonik Röhm GmbH, 
Darmstadt, Germany) cannot be ruled out. This 
compound is sometimes a component of the 
enteric coating for drug products, including 
some PERT products and mesalazine.81,85 In 
2002, a review of the use of PERT products 
stated that the continued occurrence of FC in 
the CF population emphasized the need for close 
monitoring of PERT dosing and adherence in 
patients with CF.86
Although FC occurs predominantly in 
children, it has been reported in adults.87-90 FC 
occurred in one adult with CF long after stopping 
high-dose enzyme preparations90 and, rarely, has 
occurred even in the absence of PERT, suggesting 
that it might be a complication of CF, rather than 
just a result of PERT use.91,92 In this context it 
should be noted that fibrosis of internal organs, 
particularly the pancreas, liver, and bile ducts, 
is inherent in the CF disease process,93,94 and 
an increased prevalence of CF transmembrane 
receptor mutations has been found in patients 
with primary sclerosing cholangitis,95 a disease 
characterized by progressive inflammation and 
fibrosis of the bile ducts. In a trans-abdominal 
ultrasound study assessing 83 patients with CF 
and 31 control subjects, a slight but significant 
gut wall thickening in both adults and children 
with CF was observed compared with controls.96 
There was no association of wall thickness 
with intake of high-strength enzymes, enzyme 
dosage, age, or sex. These findings are often 
mirrored in clinical practice in children with CF. 
Nevertheless, use of PERT at doses recommended 
by the CF consensus guidelines21-24 remains 
essential for most patients with CF.
Overall, review of cumulative data and 
widespread exposure to CREON in the market 
suggests that FC is an extremely rare event, 
although continued monitoring is important. In 
line with a FDA requirement for all US-approved 
PERT products, the manufacturer of CREON will 
conduct a 10-year observational study looking at 
the incidence of and risk factors associated with 
FC in patients with CF in the USA (this is a class 
requirement for all PERT manufacturers).
Potential for Viral Transmission
The active ingredient of CREON, pancrelipase, 
is a mixture of digestive enzymes extracted from 
porcine pancreas glands harvested from pigs 
raised and slaughtered for food production. 
However, as with all porcine-derived PERT 
products, the possibility of contamination of the 
starting material with swine viruses capable of 
infecting humans has to be considered.
During manufacture, reduction of viral 
pathogens starts with meticulous sourcing of 
the raw material, specific measures to reduce the 
introduction of viruses into the raw material, 
and steps in the manufacturing process to 
inactivate or remove viral contaminants. In 
compliance with national and international 
guidelines for slaughterhouses, only pancreatic 
glands from animals released fit for human 
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consumption are used. The manufacturing 
process is carried out according to Good 
Manufacturing Practices and complies with 
relevant guidelines.97-99 Viral safety of the 
medicinal product is ensured by correct 
sourcing of the material, the validated 
manufacturing process, and testing of the active 
pharmaceutical ingredient (pancrelipase).
The pancrelipase manufacturing process 
is highly effective in inactivating enveloped 
viruses; however, it does not reduce all non-
enveloped virus loads to the same extent. For 
non-enveloped viruses where contamination is 
a possibility, each virus is assessed individually 
as to the potential risk to patients. Testing is 
carried out for potentially zoonotic porcine 
viruses that may not be inactivated by the 
manufacturing process, with the rejection of 
positive batches.
Currently, the swine hepatitis E virus 
(HEV) is the only one of four non-enveloped 
viruses that is known to be zoonotic and could 
theoretically be a risk to humans. Previously, 
HEV infection in humans was thought to be 
primarily waterborne, occurring mainly in 
developing countries with poor sanitation. 
However, it is currently recognized that 
zoonotic transmission of HEV from swine 
and other animals can occur in both the 
developing and industrialized world. Swine 
HEV can be transmitted to humans by eating 
raw or undercooked swine livers and intestines, 
and by direct contact with infected animals.100 
Epidemiological data from blood donors in 
the USA and Europe show a seroprevalence 
for anti-HEV of 2%-21%.101,102 In general, HEV 
causes a self-limiting disease and patients 
typically recover without sequelae within 
2-4 weeks. Hepatitis E can present with the 
typical symptoms of viral hepatitis very 
similar to hepatitis A, but many cases are 
subclinical.101,103 It was previously thought 
that HEV (mostly genotype 1) was associated 
with a high mortality rate in pregnant women, 
particularly in certain geographic areas; 
however, more recent studies and laboratory 
data suggest that this may not be the case.100 
In addition, humans are the natural host for 
genotype 1 and it does not infect swine.100,103
CREON clinical and safety databases have 
been reviewed to look for potential HEV cases. 
Taken together, no clinically relevant risk could 
be identified in terms of CREON intake and 
any liver diseases. In particular, no association 
between CREON and potential HEV infections 
could be established. Database review has 
limitations in risk detection; however, given 
that HEV is not found in pancreatic cells,104 
together with the implementation of appropriate 
mitigation steps for HEV contamination in the 
production process, it is considered unlikely that 
a causal relationship between CREON intake and 
HEV infection exists.
In summary, the manufacturer of CREON has 
instituted measures to minimize the potential for 
zoonotic agents in the source materials, inactivate 
many such agents that may be present, and 
screen the finished product for those considered 
potentially resistant to inactivation. In addition, 
no safety concern regarding unexplained viral 
illness has been identified with over 20 years’ 
exposure history of CREON products. Therefore, 
the risk of viral illness associated with CREON 
is considered theoretical at the present time. As 
with any products derived from animal tissues, 
the potential risk for infectious disease due to 
the transmission of an infective agent cannot be 
totally excluded. In this light, the manufacturer 
will remain vigilant and will conduct a 10-year 
observational study to look at viral transmission 
of selected viruses in the CREON product, in line 
with the FDA requirement for all manufacturers 
of US-approved PERT products to carry out 
such studies.
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CONCLUSION
PERT is the standard treatment for EPI. 
It remains essential in patients with CF to 
maintain adequate nutrition and normal 
growth status, and in some patients with 
CP or post-PS to prevent malnutrition and 
excessive weight loss. PERT products are 
available worldwide and are regulated in many 
countries, most recently in the USA following 
a FDA mandate for all PERT manufacturers to 
submit new drug applications. CREON has 
been available in Europe since 1984 and in 
the USA since 1987 in various formulations 
for the treatment of EPI; a new FDA-approved 
formulation of CREON is now available in the 
USA. Extensive clinical experience and clinical 
studies have confirmed the efficacy and safety 
of CREON in patients with CF, CP, and post-PS, 
including children aged <7 years. In clinical 
studies, consistent improvements in fat and 
nitrogen absorption, stool frequency, and 
clinical symptoms have been shown compared 
with placebo or baseline. CREON appears to 
be well tolerated regardless of patient age, 
with few withdrawals due to TEAEs and a low 
frequency of treatment-related TEAEs in clinical 
studies. No safety issues have been identified 
with the various CREON formulations based 
on global post-marketing surveillance data 
collected since 1984. As requested by the FDA, 
all PERT manufacturers in the USA are now 
carrying out studies to investigate further 
the incidence and risk factors associated with 
the rare gastrointestinal complication, FC, in 
patients with CF, and also the theoretical risk 
of viral transmission from porcine-derived 
PERT products; these studies will add to the 
existing evidence for a good safety profile of 
PERT products. Together the data suggest a 
very favorable risk-benefit profile for CREON 
in the treatment of EPI.
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